JP2024543481A5 - - Google Patents
Info
- Publication number
- JP2024543481A5 JP2024543481A5 JP2024528467A JP2024528467A JP2024543481A5 JP 2024543481 A5 JP2024543481 A5 JP 2024543481A5 JP 2024528467 A JP2024528467 A JP 2024528467A JP 2024528467 A JP2024528467 A JP 2024528467A JP 2024543481 A5 JP2024543481 A5 JP 2024543481A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163278886P | 2021-11-12 | 2021-11-12 | |
| US63/278,886 | 2021-11-12 | ||
| US202263341200P | 2022-05-12 | 2022-05-12 | |
| US63/341,200 | 2022-05-12 | ||
| PCT/US2022/079567 WO2023086834A1 (en) | 2021-11-12 | 2022-11-09 | Direct replacement genome editing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024543481A JP2024543481A (ja) | 2024-11-21 |
| JP2024543481A5 true JP2024543481A5 (https=) | 2025-11-13 |
| JPWO2023086834A5 JPWO2023086834A5 (https=) | 2025-11-13 |
Family
ID=86324212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024528467A Pending JP2024543481A (ja) | 2021-11-12 | 2022-11-09 | 直接置き換えゲノム編集 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230151353A1 (https=) |
| EP (1) | EP4430207A4 (https=) |
| JP (1) | JP2024543481A (https=) |
| AU (1) | AU2022387615A1 (https=) |
| CA (1) | CA3237317A1 (https=) |
| IL (1) | IL312727A (https=) |
| MX (1) | MX2024005787A (https=) |
| WO (1) | WO2023086834A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024233949A1 (en) * | 2023-05-11 | 2024-11-14 | Replace Therapeutics, Llc | Revision of genetic material using direct replacement editing |
| AU2024344127A1 (en) * | 2023-09-22 | 2026-04-02 | Revision Bio Corporation | Dna ligase compositions, methods, and uses thereof |
| AU2024347035A1 (en) * | 2023-09-22 | 2026-04-02 | Revision Bio Corporation | Dna-dependent dna polymerase compositions, methods, and uses thereof |
| WO2025226730A1 (en) * | 2024-04-22 | 2025-10-30 | Transit Therapeutics, Inc. | Revision of genetic material using direct replacement editing |
| WO2025235828A2 (en) * | 2024-05-08 | 2025-11-13 | The General Hospital Corporation | Engineered prime editors for treating genetic deafness |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10221442B2 (en) * | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US20190330659A1 (en) * | 2016-07-15 | 2019-10-31 | Zymergen Inc. | Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase |
| US11649442B2 (en) * | 2017-09-08 | 2023-05-16 | The Regents Of The University Of California | RNA-guided endonuclease fusion polypeptides and methods of use thereof |
| CA3138576A1 (en) * | 2019-05-16 | 2020-11-19 | Trustees Of Boston University | Regulated synthetic gene expression systems |
| US20230008217A1 (en) * | 2019-12-17 | 2023-01-12 | Agilent Technologies, Inc. | Ligation-based gene editing using crispr nickase |
| US20230037794A1 (en) * | 2019-12-23 | 2023-02-09 | The Broad Institute, Inc. | Programmable dna nuclease-associated ligase and methods of use thereof |
| AU2021236683A1 (en) * | 2020-03-19 | 2022-11-17 | Intellia Therapeutics, Inc. | Methods and compositions for directed genome editing |
-
2022
- 2022-11-09 JP JP2024528467A patent/JP2024543481A/ja active Pending
- 2022-11-09 US US17/984,045 patent/US20230151353A1/en not_active Abandoned
- 2022-11-09 AU AU2022387615A patent/AU2022387615A1/en active Pending
- 2022-11-09 WO PCT/US2022/079567 patent/WO2023086834A1/en not_active Ceased
- 2022-11-09 EP EP22893813.0A patent/EP4430207A4/en active Pending
- 2022-11-09 MX MX2024005787A patent/MX2024005787A/es unknown
- 2022-11-09 IL IL312727A patent/IL312727A/en unknown
- 2022-11-09 CA CA3237317A patent/CA3237317A1/en active Pending
-
2025
- 2025-01-27 US US19/037,641 patent/US20250179468A1/en active Pending